The 20/20 platform enables theranostic, prognostic and diagnostic assay development and is especially suited for interrogation of cell signaling pathways, an evergrowing trend in development of targeted therapeutics and diagnostics in cancer. The technology was developed in collaboration with teams from the Laboratory of Pathology of the U.S. National Cancer Institute including the laboratories of Stephen Hewitt and Michael Buck. The NIH Small Business Innovative Research and NIST Advanced Technology Program programs have supported development of and improvements to L-IHC.. 20-20 Gene Systems launches L-IHC staining for biomarker identification in tumors 20/20 GeneSystems, Inc. announced today at ADAPT 2010, a business meeting focusing on advancing personalized medicine, the commercial release of their patented technology for biomarker identification in tumors and additional tissue samples.It is known that HIV virus is certainly shed through genital herpes ulcers and people with those ulcers transmit HIV to additional better. Five preliminary studies showed that it is possible to decrease the amount of HIV in the blood and genital tract through treatment to suppress HSV-2. However, those research didn’t measure whether there also was a decrease in HIV transmission. The analysis found that acyclovir decreased the occurrence of HSV-2 genital ulcers by 73 % and thus the amount of HIV present in the blood and genital tract decreased twofold. Regardless of the reduced amount of HIV within blood levels, the researchers found there was no significant difference in the transmission of HIV.